Sangamo Therapeutics (SGMO) Retained Earnings (2016 - 2025)
Historic Retained Earnings for Sangamo Therapeutics (SGMO) over the last 17 years, with Q3 2025 value amounting to -$1.6 billion.
- Sangamo Therapeutics' Retained Earnings fell 735.41% to -$1.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.6 billion, marking a year-over-year decrease of 735.41%. This contributed to the annual value of -$1.5 billion for FY2024, which is 696.41% down from last year.
- According to the latest figures from Q3 2025, Sangamo Therapeutics' Retained Earnings is -$1.6 billion, which was down 735.41% from -$1.6 billion recorded in Q2 2025.
- In the past 5 years, Sangamo Therapeutics' Retained Earnings ranged from a high of -$823.9 million in Q1 2021 and a low of -$1.6 billion during Q3 2025
- In the last 5 years, Sangamo Therapeutics' Retained Earnings had a median value of -$1.2 billion in 2023 and averaged -$1.2 billion.
- In the last 5 years, Sangamo Therapeutics' Retained Earnings crashed by 2909.79% in 2024 and then plummeted by 424.43% in 2025.
- Sangamo Therapeutics' Retained Earnings (Quarter) stood at -$956.3 million in 2021, then dropped by 20.1% to -$1.1 billion in 2022, then fell by 22.45% to -$1.4 billion in 2023, then fell by 6.96% to -$1.5 billion in 2024, then dropped by 5.68% to -$1.6 billion in 2025.
- Its Retained Earnings was -$1.6 billion in Q3 2025, compared to -$1.6 billion in Q2 2025 and -$1.5 billion in Q1 2025.